Novanta (NOVT) - 2024 Q4 - Annual Results

Revenue Performance - Novanta reported Q4 2024 GAAP revenue of $238.1 million, a 12.5% increase from Q4 2023[5] - Full year 2024 GAAP revenue reached$ 949.2 million, up 7.7% compared to 2023[10] - Revenue for Q4 2024 was $238.06 million, a 12.5% increase from$ 211.57 million in Q4 2023[30] - Full-year revenue for 2024 reached $949.25 million, up 7.7% from$ 881.66 million in 2023[30] - Novanta's acquisition activities contributed to a 9.4% revenue increase in Q4 2024 compared to the same quarter in 2023[5] - Organic revenue growth for full year 2024 was a decrease of 1.6%, excluding acquisitions and foreign currency impacts[10] - Novanta expects full year 2025 GAAP revenue of approximately $1.0 billion, representing a 5% year-over-year growth[14] Earnings and Profitability - Q4 2024 GAAP diluted EPS was$ 0.46, compared to $0.35 in Q4 2023, reflecting a 31.4% increase[8] - Full year 2024 net income was$ 64.1 million, down from $72.9 million in 2023[11] - Net income for Q4 2024 was$ 16.46 million, compared to $12.51 million in Q4 2023, reflecting a 31.5% increase[30] - The diluted adjusted EPS for Q4 2024 was$ 0.76, compared to $0.63 in Q4 2023, indicating a 20.6% growth[40] - Adjusted Operating Income for the year ended December 31, 2023, was$ 619 million, reflecting a 17.8% operating margin[46] - Adjusted Diluted EPS for the same period was $3.02, with a total of 156 million weighted average shares outstanding[46] Cash Flow and Financial Position - Operating cash flow for Q4 2024 increased 58% to$ 61.6 million, compared to $39.0 million in Q4 2023[9] - Free Cash Flow for the year ended December 31, 2024, was$ 141.5 million, which is 221% of Net Income[51] - Cash Provided by Operating Activities for the year ended December 31, 2024, was $158.5 million, compared to$ 120.1 million in 2023[51] - Cash and cash equivalents at the end of Q4 2024 were $113.99 million, up from$ 105.05 million at the end of Q4 2023[34] - Total assets increased to $1.39 billion in 2024 from$ 1.23 billion in 2023, marking a 13.3% growth[32] - Total Debt as of December 31, 2024, increased to $416.6 million from$ 354.4 million in 2023[50] - Net Debt as of December 31, 2024, was $305.2 million, up from$ 253.0 million in 2023[50] Gross Profit and Margins - Gross profit for Q4 2024 was $108.23 million, representing a gross margin of 45.4%, compared to$ 96.56 million and 45.6% in Q4 2023[30] - The company’s gross profit margin for the Medical Solutions segment decreased to 40.8% in Q4 2024 from 46.4% in Q4 2023[38] - The adjusted gross profit margin for the Automation Enabling Technologies segment improved to 51.2% in Q4 2024, up from 47.7% in Q4 2023[38] - For the year ended December 31, 2024, the adjusted gross profit reached $241,256,000, slightly down from$ 242,316,000 in 2023[38] - The company reported a GAAP gross profit of $421,545,000 for the year ended December 31, 2024, compared to$ 399,897,000 in 2023, with a margin of 44.4%[38] - Adjusted Gross Profit Margin for the year ended December 31, 2023, was 22.3%[48] Research and Development - Research and development expenses for Q4 2024 were $25.29 million, a 7.8% increase from$ 23.45 million in Q4 2023[30] Future Outlook - The company anticipates adjusted EBITDA for 2025 to be in the range of $225 million to$ 235 million[14] - Full year 2024 adjusted EBITDA increased 7% to $209.8 million, compared to$ 196.2 million in 2023[12] - Adjusted EBITDA for the year ended December 31, 2024, was $209.8 million, representing a 22.1% margin[48] - The effective tax rate for adjusted results in Q4 2024 was 23.9%, compared to 20.8% in Q4 2023[40]